Search Results - "Fortner, B. V."

DEATH ANXIETY IN OLDER ADULTS: A QUANTITATIVE REVIEW by Fortner, B V, Neimeyer, R A

“…This literature review quantitatively summarized 49 published and unpublished research studies concerning the relationship between death anxiety and age, ego…”
Get full text

Sleep and Quality of Life in Breast Cancer Patients by Fortner, Barry V, Stepanski, Edward J, Wang, Stephanie C, Kasprowicz, Sarah, Durrence, H.Heith

“…This study described sleep in a heterogeneous sample of breast cancer patients using the Pittsburgh Sleep Quality Index (PSQI) and examined the relation…”
Get full text

Description and Predictors of Direct and Indirect Costs of Pain Reported by Cancer Patients by Fortner, Barry V, Demarco, Gail, Irving, Gordon, Ashley, Jeri, Keppler, Ginny, Chavez, Jana, Munk, Jana

“…The purpose of this study was to describe direct and indirect costs associated with pain in cancer patients and to examine potential predictors of these costs…”
Get full text

The Zero Acceptance of Pain (ZAP) ™ Quality Improvement Project : Evaluation of Pain Severity, Pain Interference, Global Quality of Life, and Pain-Related Costs by Fortner, Barry V., Okon, Theodore A., Ashley, Jeri, Kepler, Ginney, Chavez, Jana, Tauer, Kurt, Clements-Thompson, Michele, Schwartzberg, Lee, Demarco, Gail, Houts, Arthur C.

“…The Zero Acceptance of Pain (ZAP)™ Quality Improvement Project was a multi-site effort to improve the lives of outpatients with cancer pain by enhancing the…”
Get full text

Year one evaluation of regional pay for quality (P4Q) oncology program by Scott, J. A., Wong, W., Olson, T., Fortner, B. V.

“…Abstract only…”
Get full text

Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) + trastuzumab (T) as first line treatment for metastatic breast cancer (MBC) by Tauer, K., Schwartzberg, L. S., Epperson, A., Fortner, B. V.

“…Abstract only 10697 Background: Platinum compounds given with taxanes have emerged as an active combination for the treatment of MBC. However, optimal…”
Get full text

Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC) by Somer, B. G., Schwartzberg, L. S., Arena, F., Epperson, A., Fu, D., Fortner, B. V.

“…Abstract only 1053 Background: ABX and XEL both have substantial single agent activity in MBC. Taxane and anti-metabolite doublets improve response rate and…”
Get full text

Randomized study of early intervention compared to standard intervention with darbepoetin-alpha (DA) for chemotherapy-induced anemia (CIA) in early stage breast cancer (ESBC) by Blakely, L., Schwartzberg, L. S., Henry, D., Sabbath, K., Fu, D., Epperson, A., Fortner, B. V.

“…Abstract only 19538 Background: Dose dense chemotherapy (DDC) with sequential doxorubicin/ cyclophosphamide followed by paclitaxel Q 14 days has an established…”
Get full text

Prevalence of insomnia and associated symptoms in patients with cancer by Stepanski, E. J., Schwartzberg, L. S., Blakely, L. J., Fu, D., Fortner, B. V.

“…Abstract only 9098 Background: High rates of insomnia have been reported in patients undergoing treatment for cancer. The etiology of insomnia in these…”
Get full text

Mild anemia is associated with greater symptom burden (SB) and reduced quality of life (QoL) in cancer patients by Schwartzberg, L., Houts, A. C., Fortner, B. V.

“…Abstract only…”
Get full text

Patient burden, resource utilization, and treatment outcomes of grade 3/4 chimeric or humanized monoclonal antibody-associated infusion reactions by Fortner, B. V., Zhu, L., Tsong, W., Burns, C., Schwartzberg, L. S.

“…Abstract only 18544 Background: Treatment with chimeric and humanized monoclonal antibodies (MAb) is associated with infusion reactions that may limit their…”
Get full text

Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC) by Mintzer, D., Schwartzberg, L. S., Cobb, P., Henry, D., Epperson, A., Fortner, B. V.

“…Abstract only 10731 Background: ABX and XEL both have substantial single agent activity in MBC. Taxane and anti-metabolic doublets improve response rate and…”
Get full text

Human resource (HR) costs of chemotherapy infusion reactions (IR) in community oncology by Ogle, J., Fortner, B. V., Moore, K., Zhu, L., Schwartzberg, L. S.

“…Abstract only 16013 Background: Chemotherapy IR are the dose limiting factor for many agents and have clinical consequences ranging from patient symptom burden…”
Get full text

The impact of anemia treatment visits on the patient and their caregiver by Tauer, K. W., Zhu, L., Fortner, B. V.

“…Abstract only…”
Get full text

The impact of anemia treatment visits on the patient and their caregiver by Tauer, K. W., Zhu, L., Fortner, B. V.

“…Abstract only…”
Get full text

A prospective investigation of chemotherapy induced neutropenia (CIN) and quality of life (QoL) by Fortner, B. V., Houts, A. C., Johnson, G., Schwartzberg, L. S.

“…Abstract only…”
Get full text

Patient-reported symptom complaints associated with 5FU + irinotecan (IRI) or oxaliplatin (OXALI) in colorectal cancer (CRC) by Blakely, J., Fortner, B. V., Kulig, K., Mao, Q., Wagner, S., Schwartzberg, L. S.

“…Abstract only…”
Get full text

Final results of the National Patient Impact Initiative by Tauer, K. W., Fortner, B. V., Zhu, L., Ma, L., Schwartzberg, L. S.

“…Abstract only…”
Get full text

Human resource costs and patient time affected by the delivery of chemotherapy and neutropenia management by Fortner, B. V., Okon, T. A., Zhu, L., Tauer, K., Moore, K., Templeton, D.

“…Abstract only…”
Get full text

Human resource costs and patient time affected by the delivery of chemotherapy and neutropenia management by Fortner, B. V., Okon, T. A., Zhu, L., Tauer, K., Moore, K., Templeton, D.

“…Abstract only…”
Get full text